Pipecuronium
Pipecuronium is a long-acting non-depolarizing neuromuscular blocking agent of the aminosteroid class that competitively antagonizes acetylcholine at nicotinic receptors at the neuromuscular junction, producing skeletal muscle relaxation. It is used as an adjunct to general anesthesia during surgical procedures requiring prolonged muscle relaxation, particularly in patients with cardiovascular disease due to its minimal cardiovascular effects.
분자량
602.9000 g/mol
LogP
4.50
TPSA
59.10 Ų
리핀스키 5의 법칙
통과
치료 영역
작용 기전
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
2D 구조
Cite this structure
Embed this structure
SMILES
CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H](N3CC[N+](C)(C)CC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CC[N+](C)(C)CC1
InChI
InChI=1S/C35H62N4O4/c1-24(40)42-32-21-26-9-10-27-28(35(26,4)23-31(32)37-15-19-39(7,8)20-16-37)11-12-34(3)29(27)22-30(33(34)43-25(2)41)36-13-17-38(5,6)18-14-36/h26-33H,9-23H2,1-8H3/q+2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
Molecular Formula
C35H62N4O4+2
HBD / HBA
- / 6
회전 가능 결합
6
무거운 원자
43
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
자주 묻는 질문
Pipecuronium is a long-acting non-depolarizing neuromuscular blocking agent of the aminosteroid class that competitively antagonizes acetylcholine at nicotinic receptors at the neuromuscular junction, producing skeletal muscle relaxation. It is used as an adjunct to general anesthesia during surgical procedures requiring prolonged muscle relaxation, particularly in patients with cardiovascular disease due to its minimal cardiovascular effects.
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Yes, Pipecuronium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201206. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 50192. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="pipecuronium"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/pipecuronium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/pipecuronium/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/pipecuronium/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="pipecuronium"></drugfyi-drug>